GEN-1 Added to Chemo Shows Benefits in Newly Diagnosed Advanced OC

GEN-1 Added to Chemo Shows Benefits in Newly Diagnosed Advanced OC
Adding Celsion's GEN-1 to standard chemotherapy — given prior to surgery — stops disease progression in patients with newly diagnosed advanced ovarian cancer and helps remove the tumor successfully during surgery, without causing significant side effects, a Phase 1b trial shows. The trial's data were presented at the American Society of Clinical Oncology-Society for Immunotherapy of Cancer (ASCO-SITC) Clinical Immuno-Oncology Symposium, held in San Francisco from Feb. 28 to March 2. The oral presentation was titled "Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with neoadjuvant chemotherapy in patients with newly diagnosed advanced-stage ovarian cancer." GEN-1 is a DNA-based immunotherapy that induces a sustained production and release of a pro-inflammatory molecule called interleukin-12 (IL-12), triggering an immune response against malignant cancer cells. The recently completed OVATION I study (NCT02480374) was designed to assess the safety and effectiveness of eight weekly treatments of GEN-1 (injected into the abdominal cavity) combined with chemotherapy in patients with newly diagnosed advanced ovarian cancer who underwent surgery after chemo. The study included four dose groups (36 mg/m2, 47 mg/m2, 61 mg/m2 and 79 mg/m2), designed to include three to six patients per group, to find the dose with the
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *